![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: RFXANK |
Gene summary for RFXANK |
![]() |
Gene information | Species | Human | Gene symbol | RFXANK | Gene ID | 8625 |
Gene name | regulatory factor X associated ankyrin containing protein | |
Gene Alias | ANKRA1 | |
Cytomap | 19p13.11 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | O14593 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
8625 | RFXANK | LZE4T | Human | Esophagus | ESCC | 2.84e-13 | 3.96e-01 | 0.0811 |
8625 | RFXANK | LZE5T | Human | Esophagus | ESCC | 7.02e-03 | 3.47e-01 | 0.0514 |
8625 | RFXANK | LZE7T | Human | Esophagus | ESCC | 4.77e-14 | 9.23e-01 | 0.0667 |
8625 | RFXANK | LZE8T | Human | Esophagus | ESCC | 1.04e-04 | 9.33e-02 | 0.067 |
8625 | RFXANK | LZE20T | Human | Esophagus | ESCC | 2.87e-07 | 2.53e-01 | 0.0662 |
8625 | RFXANK | LZE22D1 | Human | Esophagus | HGIN | 5.71e-06 | 2.08e-01 | 0.0595 |
8625 | RFXANK | LZE22T | Human | Esophagus | ESCC | 1.78e-04 | 5.56e-01 | 0.068 |
8625 | RFXANK | LZE24T | Human | Esophagus | ESCC | 1.55e-14 | 5.21e-01 | 0.0596 |
8625 | RFXANK | LZE21T | Human | Esophagus | ESCC | 3.69e-02 | 4.10e-01 | 0.0655 |
8625 | RFXANK | LZE6T | Human | Esophagus | ESCC | 1.74e-06 | 2.92e-01 | 0.0845 |
8625 | RFXANK | P1T-E | Human | Esophagus | ESCC | 3.62e-13 | 8.71e-01 | 0.0875 |
8625 | RFXANK | P2T-E | Human | Esophagus | ESCC | 5.26e-19 | 3.33e-01 | 0.1177 |
8625 | RFXANK | P4T-E | Human | Esophagus | ESCC | 1.23e-32 | 8.24e-01 | 0.1323 |
8625 | RFXANK | P5T-E | Human | Esophagus | ESCC | 2.90e-16 | 4.24e-01 | 0.1327 |
8625 | RFXANK | P8T-E | Human | Esophagus | ESCC | 2.94e-38 | 7.38e-01 | 0.0889 |
8625 | RFXANK | P9T-E | Human | Esophagus | ESCC | 1.78e-23 | 5.79e-01 | 0.1131 |
8625 | RFXANK | P10T-E | Human | Esophagus | ESCC | 1.04e-44 | 7.95e-01 | 0.116 |
8625 | RFXANK | P11T-E | Human | Esophagus | ESCC | 1.33e-19 | 6.89e-01 | 0.1426 |
8625 | RFXANK | P12T-E | Human | Esophagus | ESCC | 4.20e-40 | 7.43e-01 | 0.1122 |
8625 | RFXANK | P15T-E | Human | Esophagus | ESCC | 1.09e-24 | 5.95e-01 | 0.1149 |
Page: 1 2 3 4 5 6 7 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Breast | Precancer | ![]() |
Breast | IDC | ![]() |
Breast | DCIS | ![]() |
Cervix | CC | ![]() |
Cervix | HSIL_HPV | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000726510 | Esophagus | ESCC | Ras protein signal transduction | 201/8552 | 337/18723 | 1.44e-07 | 2.30e-06 | 201 |
GO:000726511 | Liver | Cirrhotic | Ras protein signal transduction | 119/4634 | 337/18723 | 8.16e-06 | 1.22e-04 | 119 |
GO:000726521 | Liver | HCC | Ras protein signal transduction | 187/7958 | 337/18723 | 8.89e-07 | 1.35e-05 | 187 |
GO:00072659 | Oral cavity | OSCC | Ras protein signal transduction | 185/7305 | 337/18723 | 1.95e-09 | 4.60e-08 | 185 |
GO:000726515 | Oral cavity | LP | Ras protein signal transduction | 109/4623 | 337/18723 | 8.44e-04 | 7.36e-03 | 109 |
GO:000726523 | Skin | cSCC | Ras protein signal transduction | 132/4864 | 337/18723 | 6.17e-08 | 1.57e-06 | 132 |
GO:000726519 | Thyroid | PTC | Ras protein signal transduction | 162/5968 | 337/18723 | 3.16e-10 | 1.02e-08 | 162 |
GO:000726524 | Thyroid | ATC | Ras protein signal transduction | 172/6293 | 337/18723 | 2.25e-11 | 7.96e-10 | 172 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa051527 | Esophagus | ESCC | Tuberculosis | 111/4205 | 180/8465 | 7.14e-04 | 2.32e-03 | 1.19e-03 | 111 |
hsa0461230 | Esophagus | ESCC | Antigen processing and presentation | 51/4205 | 78/8465 | 3.57e-03 | 9.34e-03 | 4.78e-03 | 51 |
hsa0515212 | Esophagus | ESCC | Tuberculosis | 111/4205 | 180/8465 | 7.14e-04 | 2.32e-03 | 1.19e-03 | 111 |
hsa04612114 | Esophagus | ESCC | Antigen processing and presentation | 51/4205 | 78/8465 | 3.57e-03 | 9.34e-03 | 4.78e-03 | 51 |
hsa0461214 | Liver | Cirrhotic | Antigen processing and presentation | 36/2530 | 78/8465 | 1.69e-03 | 8.01e-03 | 4.94e-03 | 36 |
hsa0461215 | Liver | Cirrhotic | Antigen processing and presentation | 36/2530 | 78/8465 | 1.69e-03 | 8.01e-03 | 4.94e-03 | 36 |
hsa051526 | Oral cavity | OSCC | Tuberculosis | 105/3704 | 180/8465 | 5.00e-05 | 2.04e-04 | 1.04e-04 | 105 |
hsa0461229 | Oral cavity | OSCC | Antigen processing and presentation | 47/3704 | 78/8465 | 2.37e-03 | 6.35e-03 | 3.23e-03 | 47 |
hsa0515211 | Oral cavity | OSCC | Tuberculosis | 105/3704 | 180/8465 | 5.00e-05 | 2.04e-04 | 1.04e-04 | 105 |
hsa04612113 | Oral cavity | OSCC | Antigen processing and presentation | 47/3704 | 78/8465 | 2.37e-03 | 6.35e-03 | 3.23e-03 | 47 |
hsa04612210 | Oral cavity | LP | Antigen processing and presentation | 37/2418 | 78/8465 | 2.98e-04 | 1.60e-03 | 1.03e-03 | 37 |
hsa0515221 | Oral cavity | LP | Tuberculosis | 65/2418 | 180/8465 | 1.60e-02 | 4.92e-02 | 3.17e-02 | 65 |
hsa0461237 | Oral cavity | LP | Antigen processing and presentation | 37/2418 | 78/8465 | 2.98e-04 | 1.60e-03 | 1.03e-03 | 37 |
hsa0515231 | Oral cavity | LP | Tuberculosis | 65/2418 | 180/8465 | 1.60e-02 | 4.92e-02 | 3.17e-02 | 65 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 2 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RFXANK | SNV | Missense_Mutation | c.97N>C | p.Asp33His | p.D33H | O14593 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.883) | TCGA-C8-A274-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | |
RFXANK | SNV | Missense_Mutation | novel | c.240N>A | p.Asn80Lys | p.N80K | O14593 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-JL-A3YW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
RFXANK | insertion | Frame_Shift_Ins | novel | c.555_556insCAACCGGCAGCGAGGGAACGAGG | p.Tyr186GlnfsTer26 | p.Y186Qfs*26 | O14593 | protein_coding | TCGA-BH-A0E2-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | ||
RFXANK | SNV | Missense_Mutation | novel | c.575C>T | p.Thr192Met | p.T192M | O14593 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-ZJ-AAXD-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
RFXANK | SNV | Missense_Mutation | rs749859039 | c.595N>T | p.Arg199Cys | p.R199C | O14593 | protein_coding | tolerated(0.11) | probably_damaging(0.997) | TCGA-D5-6530-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
RFXANK | insertion | Frame_Shift_Ins | novel | c.446_447insC | p.His151ProfsTer30 | p.H151Pfs*30 | O14593 | protein_coding | TCGA-DM-A1HB-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | ||
RFXANK | SNV | Missense_Mutation | novel | c.517G>A | p.Val173Met | p.V173M | O14593 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
RFXANK | SNV | Missense_Mutation | c.685N>A | p.Leu229Ile | p.L229I | O14593 | protein_coding | tolerated(0.18) | possibly_damaging(0.738) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
RFXANK | SNV | Missense_Mutation | c.655G>A | p.Glu219Lys | p.E219K | O14593 | protein_coding | tolerated(0.05) | probably_damaging(0.951) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
RFXANK | SNV | Missense_Mutation | c.638N>A | p.Gly213Asp | p.G213D | O14593 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AX-A0J1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |